Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology - KPVI News 6
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Comments
Post a Comment